Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QuantRx Biomedical, a broad-based diagnostic company, has received the FDA 510(k) clearance for its RapidSense drugs-of-abuse methamphetamine test.
Subscribe to our email newsletter
The RapidSense methamphetamine test is said to be the first of QuantRx’s drugs-of-abuse (DOA) tests based solely on its proprietary technology approved by the FDA. The RapidSense methamphetamine test is a one-step positive read lateral flow device intended for use in the professional markets.
William Fleming, president of diagnostics at QuantRx, said: “The new clearance allows the company to provide its customers with a new and innovative product for DOA testing, which we believe will complement our current sales efforts and allow us to expand beyond our traditional original equipment manufacturer product base.”